Bibliography for: "A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution"

Michael H. Gold "A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution". Journal of Drugs in Dermatology. FindArticles.com. 23 Dec, 2009. http://findarticles.com/p/articles/mi_m0PDG/is_1_4/ai_n9511656/

Journal of Drugs in Dermatology

View more issues:

Articles in Jan-Feb, 2005 issue of Journal of Drugs in Dermatology

• ZD1839 for recurrent or metastatic squamous cell carcinoma of the skin
• Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study
  by Tina S. Alster
• MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with melanoma
• Leptin to treat lipodystrophy
• The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris
  by Alan R. Shalita
• Multiple basal cell carcinomas in a young adult treated with imiquimod 5%: a case report and literature review
  by Akiva Bergman
• FDA plans for increased monitoring of Accutane
• Tetracycline in preventing skin rash in patients who are receiving drugs such as gefitinib and cetuximab for cancer
• Longevity of effects of injectable products for soft-tissue augmentation
  by Philip Werschler
• Simultaneous acral nodular eruption and flagellate erythema caused by bleomycin
  by Maryann Mikhail
• Hylaform Plus filler approved for facial wrinkles and folds
• Lidocaine and Epinephrine solution for iontophoretic induction of analgesia approved
• Interferon beta in treating patients with metastatic cutaneous melanoma or ocular melanoma
• Anti-CD20 in systemic lupus erythematosus
• Campath-1H for treating adult T-cell leukemia
• Innovative uses of imiquimod
  by Ronald B. Vender
• Telemedicine legal update 2004: reimbursement, the doctor-patient relationship, teleconsultations, and the legal status of digital images
  by Noah Scheinfeld
• FDA warns Remicade may be associated with increased risk of lymphoma
• To study the use of humanized CD25 in preventing the relapse of psoriasis vulgaris
• Chemical and genetic effects of the experimental anti-cancer drugs in cheek cells in cancer patients
• Porokeratosis: a solitary oral lesion
  by Matthew J. Darling
• Clindamycin foam 1% gains FDA approval for the treatment of acne vulgaris
• Gene therapy and vaccine treatment to treat metastatic melanoma
• Interleukin-7 and peptide vaccine to treat metastatic melanoma
• Skin Cancer Foundation update
• Dual wavelength laser receives FDA clearance
• Iatrogenic contact dermatitis due to propylene glycol
  by Rebecca Lu
• New drug application submitted for IV meropenem
• A multicenter, open-label study to assess the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to Candida albicans
  by Elizabeth Gallup
• Complete resolution of generalized lichen planus after treatment with thalidomide
  by Jennifer L. Maender
• FDA grants market approval for Captique injectable gel
• New chip implant allows for emergency retrieval of medical information
• Vaccine treatment in combination with IL-2 and treated lymphocytes for advanced melanoma
• Intravenous mepolizumab in subjects with hypereosinophilic syndromes
• A letter from the guest editor
  by Dan Siegel
• A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution
  by Michael H. Gold
• Electronic prescribing: an update
  by Mark D. Kaufmann
• Connetics submits New Drug Application for Velac
• Monoclonal antibody treatment for systemic lupus erythematosus
• Infliximab to treat non-infectious scleritis
• A dermatologist's response to the American Academy of Pediatrics guidelines on head lice
  by Craig G. Burkhart
• Online drug information for dermatology patients
  by Amanda Oakley
• Phase II randomized bilateral comparison of topical targretin gel 1% in alopecia areata
• Peptide-sensitized lymphocytes plus melanoma peptide immunization followed by IL-2 to treat patients with melanoma
• FDA grants approval for new oral solution of Levaquin
• Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids
  by Joseph B. Bikowski
• Palisaded encapsulated neuroma—a classic presentation of a commonly misdiagnosed neural tumor
  by Olga Golod
• New laser system approved for endovenous treatment of varicose veins
• Ultraviolet light therapy for systemic lupus erythematosus
• The potential utility of statin vaginal gels in the prevention of HIV transmission
  by M.R. Namazi
• Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial
  by Alireza Firooz
• Washington Whispers
• Aventis announces approval of extended release Allegra-D
• Radiation therapy in preventing metastatic cancer in patients who have diagnostic procedures to identify malignant mesothelioma
• Lymphocyte-depleting conditioning followed by infusion of engineered lymphocytes and vaccination to treat advanced melanoma